Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Matza, LS; Boye, KS; Jordan, James O.; Norrbacka, Kirsi; Gentilella, R.; Browne, Chantelle; Federici, M. Orsini; Stewart, KD

doi:10.1016/j.jval.2017.08.1091

Cited by 4 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean EQ-5D-3L index score calculated using the Italian tariffs (0.91) [41] is the same as the mean score in a previous utility study conducted in a sample of patients with T2D in Italy [22]. The score range (0.36-1.00) and standard deviation (0.11) suggest that the sample was diverse in terms of health status.…”

Section: Sample Descriptionmentioning

confidence: 70%

“…In contrast, vignette-based methods are well-suited for isolating the utility impact of specific treatmentrelated attributes and are commonly used in studies of treatment process utilities [1]. Several previously published studies used this approach to estimate the utility impact of diabetes treatment attributes [21][22][23][24]. The utilities derived in these previous studies have been used in a range of published cost-utility analyses (CUAs) of treatments for diabetes [25][26][27][28][29][30].…”

Section: Overview Of Study Designmentioning

confidence: 99%

See 1 more Smart Citation

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Sample Descriptionmentioning

confidence: 70%

Section: Overview Of Study Designmentioning

confidence: 99%

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…ROA is often a primary focus of research on treatment process utilities. A range of published studies have estimated utility differences between oral and injectable treatment, and the oral ROA tends to be preferred as indicated by higher utility scores [8][9][10]. Because studies estimating process utility usually use vignette-based methods [1], the utility differences between oral and injectable ROA are mostly based on valuations of health state descriptions that vary with regard to ROA.…”

Section: Introductionmentioning

confidence: 99%

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

et al. 2021

View full text Add to dashboard Cite

Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D). Methods Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection. Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral semaglutide, 0.878 for dulaglutide injection, and 0.859 for semaglutide injection (with higher scores indicating greater preference). All pairwise comparisons found statistically significant differences between utilities (p < 0.01), except the comparison between oral semaglutide and the dulaglutide injection (p = 0.49). Conclusions Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient preferences for treatment process when selecting medications for patients in clinical settings.

show abstract

“…[35][36][37][38] Attributes of the injection device and procedures that have been shown to contribute to patient preference include needle handling requirements, steps for preparing the injection device, dose frequency and overall ease of use. 10,[39][40][41][42] The dulaglutide and semaglutide injection devices have been compared in a previous study in which preferences were based on descriptions of the devices with images from the device instructions for use, rather than actual experience of using the devices. 43 The primary objective of the current study was to examine preference between the dulaglutide and semaglutide injection devices after participants had been trained to inject with both devices and then used them to administer injections into an injection pad.…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies have found that patients with T2D consistently prefer injection devices that are easy to use . Attributes of the injection device and procedures that have been shown to contribute to patient preference include needle handling requirements, steps for preparing the injection device, dose frequency and overall ease of use …”

Section: Introductionmentioning

confidence: 99%

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Matza

Boye

Stewart

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001). Conclusions Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.

show abstract

Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Cited by 4 publications

References 29 publications

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Contact Info

Product

Resources

About